InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

April 18, 2024

Read More »

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

April 16, 2024

Read More »

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

April 4, 2024

Read More »

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

March 20, 2024

Read More »

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

February 13, 2024

Read More »

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

February 9, 2024

Read More »

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

January 18, 2024

Read More »

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

January 16, 2024

Read More »

InMed Announces Results of 2023 Annual General Meeting

December 19, 2023

Read More »

InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration

November 29, 2023

Read More »

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

November 14, 2023

Read More »

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

November 2, 2023

Read More »

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

October 26, 2023

Read More »

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

October 24, 2023

Read More »

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

October 24, 2023

Read More »

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

September 29, 2023

Read More »

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

September 22, 2023

Read More »

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

September 7, 2023

Read More »

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

July 21, 2023

Read More »

InMed Provides Update on BayMedica Rare Cannabinoid Business

July 20, 2023

Read More »